 | This articlerelies largely or entirely on asingle source. Relevant discussion may be found on thetalk page. Please helpimprove this article byintroducing citations to additional sources. Find sources: "Sino Biopharmaceutical Limited" – news ·newspapers ·books ·scholar ·JSTOR(January 2020) |
| Company type | Public |
|---|---|
| |
| Industry | Pharmaceutical |
| Founded | 2000 |
| Headquarters | |
Area served | China |
Key people | Ms. Tse, Theresa Y Y (Chairwoman of the Board)[1][2] |
Number of employees | 25,000 (2024) |
| Website | Sino Biopharmaceutical Limited |
Sino Biopharmaceutical Limited (SEHK: 1177|Hang Seng Index component) (simplified Chinese:中国生物制药有限公司;traditional Chinese:中國生物製藥有限公司), shortlySino Biopharm, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China (Hong Kong-listed) 25 Index in 2020.[3]
The Group’s principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (“CT Tianqing”), Beijing Tide Pharmaceutical Co. Ltd. (“Beijing Tide”), Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTT”), Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (“Jiangsu CT Fenghai”), Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. (“Jiangsu CT Qingjiang”) and invoX Pharma Limited (“invoX”). Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia.[4]
Ms. Y. Y. Tse - Exec. Chairman... Mr. Eric S. Y. Tse - CEO & Exec. Director
Y. Y. Tse - Executive Chairwoman of the Board, S. Y. Tse - Chief Executive Officer, Executive Director
 | This Chinese corporation or company article is astub. You can help Wikipedia byadding missing information. |
